Relationship between mean platelet volume and le ventricular systolic function in patients with metabolic syndrome and ST-elevation myocardial infarction Abstract Purpose: Mean platelet volume (MPV) is an indicator of platelet activation, which is a central process in the pathophysiology of coronary heart disease. Metabolic syndrome (MS) may lead to worsened le ventricular systolic function by causing recurrent thrombotic events and by aggravating systemic in ammation in the course of acute myocardial infarction. e present study was designed to investigate the relationship between MPV and le ventricular systolic function in patients with metabolic syndrome who had rst ST-elevation myocardial infarction.
Metabolic syndrome (MS) is characterized by clustering of closely associated interdependent atherosclerotic risk factors, including insulin resistance, high blood pressure, low level of high-density lipoprotein (HDL) cholesterol, high triglyceride level, high plasma glucose concentration and obesity. Its prevalence has gradually increased in the developed world [1] . An increased prevalence of metabolic syndrome has been shown in patients with acute myocardial infarction (AMI) [2] . MS causes an increased risk for coronary artery disease, cardiovascular morbidity and mortality [2, 3] . Accelerated atherosclerosis, increased tendency to thrombosis and in ammation may have a role in increased cardiovascular disease-related morbidity and mortality in MS. is syndrome is also associated with a hypercoagulable state, characterized by increased levels of clotting factors as well as inhibition of the brinolytic pathway [4] . MS may lead to worsened of le ventricular systolic function by causing recurrent thrombotic events and by aggravating systemic in ammation in the course of AMI.
Mean platelet volume (MPV) is an indicator of platelet activation [5] , which has an important role in the pathophysiology of coronary artery disease related complications [6] . After erosion or rupture of atherosclerotic plaques in coronary arteries, platelet activation plays a critical role in the prothrombotic events leading to AMI. Elevated MPV levels have been identi ed as an independent risk factor for myocardial infarction in patients with coronary heart disease and for death or recurrent vascular events a er MI [7, 8] .
Le ventricular ejection fraction (EF) is a widely-used parameter for evaluating le ventricular systolic function in daily practice and has been shown to be a powerful independent predictor of prognosis a er AMI [9] . e goal of this study was to evaluate the relationship between MPV levels and le ventricular systolic function in patients with metabolic syndrome who had rst ST-elevation AMI.
Methods
Between May 2005 and January 2007, 81 consecutive patients with MS, referred for the rst ST-elevation AMI were prospectively included. e local ethic committee approval and informed consent from each patient was obtained. Inclusion criteria included continuous chest pain that lasted > 30 minutes within the preceding 12 hours, ST-segment elevation more than 1 mm in two contiguous leads on the 12 leads electrocardiograph and rst ST elevation AMI who had MS. Exclusion criteria were renal dysfunction (creatinine >2.5 mg/dl), previous myocardial infarction, Killip class ≥2, previous percutaneous coronary inrervention or coronary artery bypass surgery, valvular heart disease, subacute period (accepted as admission >12 h), inadequate echocardiographic image quality, hematological disorders, malignant disease and acute or chronic infection.
Reperfusion was determined by evaluating ST segment changes in the 12 lead electrocardiograph. Successfully reperfusion was described as 70% ST segment resolution 90 min a er reperfusion therapy.
Diagnostic criteria for metabolic syndrome e diagnosis of MS was based on the ATP III clinical de nition of the metabolic syndrome [1] . is requires the presence of ≥3 of the following: 1) abdominal obesity (waist circumference > 102 cm in men and > 88 cm in women); 2) high triglyceride level (> 150 mg/dl); 3) low HDL-cholesterol level (< 40 mg/dl for men and < 50 mg/dl for women); 4) high blood pressure (systolic > 130 mmHg or diastolic > 85 mmHg, or on antihypertensive medication) and 5) a high fasting plasma glucose concentration (> 110 mg/dl).
Biochemical measurements
Automated analyzers were used for the biochemical and hematological measurements. Blood samples for the biochemical measurements were drawn without stasis at 7-8 a.m. a er 20 min of supine rest following a fasting period of 12 h. Glucose, creatinine and lipid pro le were determined by standard methods. Blood samples for the MPV measurements were drawn within the rst 1 hour a er admission, were collected in tubes containing Na-citrate and were analyzed within 2 hours. An automatic blood counter (A Cell-Dyn 3500, Abbott, IL, USA) was used for whole blood analysis. e normal range for MPV in our laboratory is 7.0 to 11.0 .
Echocardiography analysis
e echocardiographic examination was done as soon as clinical stability of the patients was achieved a er admission to coronary intensive care unit (mean 2.4 days). All patients were evaluated by two-dimensional echocardiography by using a Vivid 7 system (General Electric) with a 2.5-5 MHz transducer. Le ventricular systolic functions were assessed by EF determined using the modi ed Simpson method. End-systolic and end-diastolic LV cavity volumes were computed from the area measurement obtained from apical 2-and 4-chamber views at end-systole and end-diastole, respectively and averaged [10] . Patients were divided into two groups, according to LVEF, to evaluate the le ventricle systolic function: patients who had depressed le ventricle systolic function (group A = LVEF ≤50%), and patients who had preserved le ventricle 
Results
Of 92 patients enrolled with rst ST-elevation AMI and MS, 11 patients were excluded due to exclusion criteria. Of the remaining 81 patients (60 men, 21 women), the mean age was 57.5±10.3 years (range 33 to 80). e mean EF of the patients was 47.1±8.4%. ere were no statistically signi cant di erences between groups A and B according to age, gender, reperfusion treatment rate, time between reperfusion treatment and AMI, successfully reperfusion, family history for coronary artery disease, time between AMI and echocardiography, presence of hypertension or diabetes mellitus, and smoking habit (p >0.05). e number of patients with anterior wall myocardial infarction was signi cantly higher in group A than group B (58.3% vs. 30.3%; p=0.01). e main characteristics of study populations are shown in Table 1 . MPV was signi cantly higher in group A than group B (9.94±1.09 vs. 9.14±1.05 ; p=0.02). e hematological parameters of study population are shown in Table 2 .
Logistic regression analysis showed an independent relationship between MPV and deteriorated le ventricular sys- 
Discussion
In the present study the relationship between MPV and le ventricle systolic function was investigated in patients with MS who had rst ST-elevation AMI. In this selected population, patients with depressed le ventricle function had signi cantly higher MPV values than patients with preserved le ventricular function.
Platelets play an important role in the pathogenesis, morbidity, and mortality of acute coronary syndromes [11] . Previous studies have demonstrated that there is a close relationship between MPV and cardiovascular risk factors, such as metabolic syndrome, diabetes mellitus, hypertension and hypercholesterolemia [12] [13] [14] [15] .
Patients with MS are at increased risk for developing coronary heart disease as well as increased morbidity and mortality from cardiovascular disease [3, 4] . Metabolic syndrome is thought to have a crucial role in the development of cardiovascular complications and a greater likelihood of thrombosis, complicating vessel injury such as atherosclerotic plaque rupture [16] [17] [18] .
ere are several mechanisms which are responsible for increased propensity to thrombosis.
ese mechanisms include increased activation of platelets [19] , increased production and release of thromboxane A2 by platelets [20] , increased platelet reactivity due to the direct e ect of hyperglycemia [21] and vascular dysfunction due to decreased vascular endothelial production of prostacyclin and nitric oxide [22] .
Increased platelet size re ects increased platelet activity. Mean platelet volume can re ect changes in the level of platelet stimulation and the rate of platelet production [23] . Hemostatically reactive platelets and larger platelets have more granules and adhesion receptors, which result in decreased bleeding time, an indication of increased activation [24] . On these grounds, MPV could be accepted as a parameter of platelet activity and has become a prognostic factor in coronary heart disease [25] . Previous studies have demonstrated a close relationship between MPV and AMI [8] , unstable coronary syndromes [26] , slow coronary ow [27] and coronary artery ectasia development [28] . High MPV values were found to be associated with unsuccessful reperfusion a er both primary percutaneous coronary intervention and brinolytic therapy [29, 30] . In addition, increased platelet activity may be associated with recurrent thrombotic events and no-re ow phenomenon, which are, in turn, associated with poorer le ventricular function. Martin et al. reported that elevated MPV were associated with both death and recurrent MI a er rst AMI [8] . In addition, Sezer et al. found that elevated MPV was associated with adverse microvascular outcomes in AMI [31] . In the light of these ndings, it is possible to conclude that increased platelet activity may be more closely associated with worse le ventricular EF in patients with MS with their rst AMI as a result of their procoagulable and proin ammatory states.
e rate of cardiovascular risk factors, e.g., hypertensions and diabetes, in the patients with metabolic syndrome is higher than in individuals without metabolic syndrome. In addition, the presence of metabolic syndrome is shown to be associated with elevated in ammation [1, 4] . All these factors can trigger platelet activity by activating various pathways. Augmented platelet activity in an acute myocardial infarct (AMI) has been demonstrated to be associated with unsuccessful reperfusion, repeated myocardial infarcts and increased no-re ow phenomenon [8, 29, 31] . Particularly, impaired microvascular circulation due to thrombosis is expected during ampli ed thrombocyte activity [31] . All of these factors could be responsible, at least in part, for the le ventricular systolic dysfunctions at di erent extends.
e elevated MPV may be used as a marker for accelerated in ammatory and thrombogenic process and may be associated with poorer outcomes in patients with MS attending for AMI.
e main limitation of this study was relatively small sample size. Nevertheless, we think that the increased levels of MPV in the patients with le ventricular systolic dysfunctions are still clinically signi cant and not entirely incidental. Further studies with larger populations are needed to clarify potential association between MPV in the patients with le ventricular systolic dysfunctions. Second, unidenti ed confounders may have an in uence on MPV levels. ird, the patients' medications were not recorded but all patients included in the study were treated according to recent guidelines.
Conclusions
Elevated MPV on admission can be associated with degree of le ventricular systolic dysfunction in patients with metabolic syndrome who had rst ST-elevation AMIand, thus, shows potential for use as a prognostic marker.
